Weight Loss & Metabolic Health
What Is Zepbound?
Last reviewed: May 2026 · Haute MD Editorial Team
Zepbound is the brand name for tirzepatide approved by the FDA in 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, and in 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the same dual GIP/GLP-1 receptor agonist as Mounjaro, made by Eli Lilly, and is currently the most effective FDA-approved medication for weight loss.
How Zepbound works
Zepbound activates two gut hormone pathways at once — GLP-1 and GIP. GLP-1 suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin release. GIP further enhances insulin secretion and appears to improve how adipose tissue handles fat. The dual action produces stronger appetite suppression, greater insulin sensitivity, and meaningfully larger weight loss than single-agonist GLP-1s in head-to-head trials.
Clinical results and dosing
In the SURMOUNT-1 trial of adults without diabetes, Zepbound produced average weight loss of 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks — versus 3.1% with placebo. Roughly one-third of patients lost 25% or more. In SURMOUNT-OSA, Zepbound reduced sleep apnea events by 25-29 per hour and led to FDA approval for OSA in 2024. Dosing starts at 2.5 mg weekly and titrates monthly through 5, 7.5, 10, 12.5, and up to 15 mg maintenance.
Side effects and long-term considerations
Side effects are typical of the GLP-1 class: nausea, vomiting, diarrhea, constipation, and reduced appetite, mostly mild and dose-titration related. Serious but rare risks include pancreatitis, gallbladder disease, and the boxed warning for thyroid C-cell tumors. Preserving lean mass during rapid weight loss requires protein intake of 0.7-1.0 g per pound of goal body weight and resistance training 2-3 times weekly. As with all obesity medications, stopping the drug typically leads to substantial weight regain because the underlying biology persists.
Frequently Asked Questions
How much weight loss should I expect on Zepbound?
Average weight loss in clinical trials was about 21% at the 15 mg dose over 72 weeks — the highest yet seen with an approved weight loss medication. One in three patients lost 25% or more.
Is Zepbound better than Wegovy?
In indirect comparisons and the SURMOUNT-5 head-to-head trial, tirzepatide produced greater weight loss than semaglutide. Individual response and side effect tolerance vary, so the 'best' drug depends on the patient.
Does Zepbound treat sleep apnea?
Yes — Zepbound is the first medication FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial showing meaningful reductions in apnea-hypopnea index alongside weight loss.
Will insurance cover Zepbound?
Coverage is expanding but remains inconsistent. Many commercial plans cover Zepbound for obesity with prior authorization; coverage for the OSA indication is newer. Manufacturer savings programs are available for eligible patients.
Get Help Now
Speak with a Haute MD Internal Medicine physician
Dr. Alexander Golberg
Internal Medicine · New York, NY
View Profile
Dr. Kern Brar
MD
Internal Medicine · Oceanside, CA
View ProfileAre you a Internal Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · WEIGHT LOSS & METABOLIC HEALTH
What Is Mounjaro?
Mounjaro is tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes. It's the same molecule as Zepbound, the weight-loss-approved version.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
What Is Wegovy?
Wegovy is semaglutide approved by the FDA specifically for chronic weight management. It's the same molecule as Ozempic, dosed up to 2.4 mg weekly, with average weight loss of 15%.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
How Much Weight Can You Lose on GLP-1 Therapy?
Average weight loss is 15% on semaglutide (Wegovy) and 21% on tirzepatide (Zepbound) over 68-72 weeks. Top responders lose 25%+. Lifestyle integration significantly improves results.
Read Guide